홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.1
  1. 홈
  2. /화합물

살부타몰

Salbutamol

HCID 2083
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
18559-94-9
표준 SMILES
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
InChIKey
NDAUXUAQIAJITI-UHFFFAOYSA-N
분자식
C13H21NO3
평균 분자량
239.31 g/mol
단동위원소 질량
239.15214353

개요

Albuterol is a member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It has a role as a beta-adrenergic agonist, a bronchodilator agent, a xenobiotic and an environmental contaminant. It is a member of phenylethanolamines, a member of phenols and a secondary amino compound.

이름 및 식별자

우선 이름
Salbutamol
IUPAC
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
현지명
살부타몰
영어명
Salbutamol
분자식
C13H21NO3
분자량
239.32

이름 및 동의어

Salbutamolalbuterol18559-94-9VentolineProventil HFACobutolinSalbutamolumSalbuventAsmavenAsthalinAerolinSalamol
이름 더 보기
살부타몰알부테롤ventolinLEVALBUTEROL HCLproventilVolmaxR-SALBUTAMOL HCLsalbutamolfreebaseah3365
Asmol4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolVentilanVentodisksAiromirEtinolineVospire4-(2-(tert-Butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol

데이터베이스 식별자

CAS
18559-94-9
PubChem CID
2083
DTXSID
DTXSID5021255
ChEMBL
CHEMBL714
ChEBI
CHEBI:2549
UNII
QF8SVZ843E
EC Number
242-424-0
Nikkaji
J10.899E

물성

구조 계산 물성

XLogP
0.3
극성 표면적
72.7 Ų
수소 결합 공여자 수
4
수소 결합 수용자 수
4
회전 가능 결합 수
5
무거운 원자 수
17
형식 전하
0
복잡도
227

실험 및 물리화학적 성질

Chemical ClassesPharmaceutical
DrugsPharmaceuticals
LogP · 3건

log Kow = 0.64 /Estimated/

1.4

-0.39

Color/Form · 2건

White to off-white crystalline solid

Crystalline powder from ethanol-ethyl acetate or ethyl acetate-cyclohexane

Solubility · 4건

Soluble in ethanol, sparingly soluble in water, and very soluble in chlorform.

Soluble in most organic solvents.

In water, 1.43X10+4 mg/L, temp not specified

2.15e+00 g/L

Human Drugs · 5건

Breast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Melting Point · 3건

147-149

151 °C (Lunts); 157-158 °C (Collins)

157 - 158 °C

Vapor Pressure8.9X10-9 mm Hg at 25 °C /Estimated/

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (98%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 51 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 2건

REACH registered substance: Salbutamol (EC: 242-424-0)

1,3-Benzenedimethanol, .alpha.1-(1,1-dimethylethyl)aminomethyl-4-hydroxy-: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 1,3-Benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-: Environment tier I assessment
FDA Requirements · 3건

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl albuterol, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl albuterol sulfate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Albuterol Sulfate/

Certain other dosage form new animal drugs. Albuterol. Indications for use: for the immediate relief of bronchospasm and bronchoconstriction associated with reversible airway obstruction in horses. Limitations: Not for use in horses intended for food.

Hazard Classes and CategoriesAcute Tox. 4 (98%)

안전 및 보호

화학 및 산업

약리 정보

ATC Code · 6건

R03AC02

R - Respiratory system

R - Respiratory system

QR - Respiratory system

QR - Respiratory system

R03AC02

Protein BindingSalbutamol is only weakly bound to plasma proteins.
Pharmacodynamics · 1건

Salbutamol (INN) or albuterol (USAN), a moderately selective beta(2)-receptor agonist similar in structure to terbutaline, is widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases. The R-isomer, levalbuterol, is responsible for bronchodilation while the S-isomer increases bronchial reactivity. The R-enantiomer is available and sold in its pure form as levalbuterol and subsequently may produce fewer side-effects with only the R-enantiomer present - although this has not been formally demonstrated. After oral and parenteral administration, stimulation of the beta receptors in the body, both beta-1 and beta-2, occurs because (a) beta-2 selectivity is not absolute, and (b) higher concentrations of salbutamol occur in the regions of these receptors with these modes of administration. This results in the beta-1 effect of cardiac stimulation, though not so much as with isoprenaline, and beta-2 effects of peripheral vasodilatation and hypotension, skeletal muscle tremor, and uterine muscle relaxation. Metabolic effects such as hyperinsulinemia and hyperglycemia also may occur, although it is not known whether these effects are mediated by beta-1 or beta-2 receptors. The serum potassium levels have a tendency to fall.

Mechanism of Action · 5건

In vitro studies and in vivo pharmacologic studies have shown that salbutamol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. Although beta2­ adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1 adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. Activation of beta2-adrenergic receptors on airway smooth muscle leads to the activation of adenyl cyclase and to an increase in the intracellular concentration of cyclic-3′,5′-adenosine monophosphate (cyclic AMP). This increase of cyclic AMP leads to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Salbutamol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Salbutamol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Salbutamol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes. A measurable decrease in airway resistance is typically observed within 5 to 15 minutes after inhalation of salbutamol. The maximum improvement in pulmonary function usually occurs 60 to 90 minutes after salbutamol treatment, and significant bronchodilator activity has been observed to persist for 3 to 6 hours.

관련 반응

19건
반응 기록 만들기
HRID 48093 반응식
HRID 48093생성물로uspto-grants-2004_03
HRID 219482 반응식
HRID 219482생성물로uspto-grants-2012_06
HRID 333510 반응식
HRID 333510생성물로uspto-grants-2014_11
HRID 403095 반응식
HRID 403095생성물로uspto-grants-2014_06
HRID 1078016 반응식
HRID 1078016반응물로uspto-grants-1996_08
HRID 1085997 반응식
HRID 1085997반응물로uspto-grants-1991_04
HRID 1383790 반응식
HRID 1383790반응물로uspto-grants-2001_07
HRID 1383791 반응식
HRID 1383791반응물로uspto-grants-2001_07
이전1 / 3 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
Optical Rotation
MW: 275.58. Crystallized as the monohydrate; changes crystalline form at 175 °C; decopmoses 188-195 °C. Specific optical rotation: -32.2 deg @ 20 °C/D (c = 0.1 in water) /(R)-form hydrochloride/
Henry's Law ConstantHenry's Law constant = 6.4X10-16 atm-cu m/mole at 25 °C /Estimated/
Physical DescriptionSolid
Dissociation Constants · 2건

10.3

pKa1 = 9.2 (amine nitrogen); pKa2 = 10.7 (phenolic -OH) /Estimated/

물리화학적 성질

녹는점
157 · 157-160℃
끓는 점
381.97 °C · 381.97°C (rough estimate)
밀도
1.07 · 1.0700 (rough estimate)
굴절률
1.48 · 1.4800 (estimate)
저장 조건
2 · 2-8°C
용해도
물에 거의 녹지 않으며, 에탄올(96%)에 녹습니다.
산도 계수 (pKa)
9.07 · pKa 9.07(H2O t = 25.0±0.05 I = 0.10) (Uncertain);10.37(H2O t = 25.0±0.05 I = 0.10) (Uncertain)
물리적 상태
Solid
색상
하얀색
수용성
17.95 g/L · 17.95g/L(25℃)
Merck
13 · 13,215
BRN
6405698 · 6405698
Henry's Law Constant
1.5 · 1.5×1010 mol/(m3Pa) at 25℃, HSDB (2015)
BCS Class
3 · 3
안정성
안정적이지만 빛에 민감합니다. 강한 산화제와 호환되지 않습니다.
주요 응용
임상 시험
InChI
1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
InChIKey
NDAUXUAQIAJITI-UHFFFAOYSA-N
SMILES
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
LogP
0.64 · 0.64
EPA
1 · 1,3-Benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- (18559-94-9)

화학적 성질

solid

Storage Conditions · 2건

Albuterol sulfate tablets, extended-release tablets, and the oral solution should be stored at 2-30 °C, unit-dose packages of the extended-release tablets should be protected from excessive moisture. /Albuterol sulfate/

Preparations containing albuterol or albuterol sulfate should be stored in well-closed, light resistant containers. Commercially available metered-dose albuterol and albuterol sulfate inhalers should be stored at 15-30 adn 15-25 °C, respectively.

Disposal Methods · 1건

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

독성 정보

Interactions · 4건

Following single-dose IV or oral administration of albuterol to healthy individuals who had received digoxin for 10 days, a 16-22% decrease in serum digoxin concentration was observed.

Epinephrin, other orally inhaled sympathomimetic amines: May increase sympathomimetic effects and risk of toxicity. Avoid use together /with albuterol/.

MAO inhibitors, tricyclic antidepressants: Serious cardiovascular effects and risk of toxicity. Avoid use together /with albuterol/.

Propanolol, other beta blockers: May antagonize effects of albuterol. Use together cautiously.

Environmental Fate · 3건

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 23(SRC), determined from a water solubility of 1.41X10+4 mg/L(2) and a regression-derived equation(3), indicates that albuterol is expected to have very high mobility in soil(SRC). However, the estimated pKa of albuterol is 10(4), indicating that this compound may partially exist in the protonated form in the environment. Cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(5), suggesting that mobility may be much lower in some soils(SRC). Volatilization of albuterol from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 6.4X10-16 atm-cu m/mole(SRC), using a fragment constant estimation method(6). Albuterol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 8.9X10-9 mm Hg(SRC), determined from a fragment constant method(7).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 23(SRC), determined from a water solubility of 1.41X10+4 mg/L(2) and a regression-derived equation(3), indicates that albuterol is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 6.4X10-16 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). The pKa1 and pKa2 of albuterol are 9.2 and 10.7(5), respectively, indicating that this compound will partially exist in the protonated in the environment and cations generally adsorb more strongly to suspended solids and sediment than their neutral counterparts(6). According to a classification scheme(7), an estimated BCF of 3(SRC), from its water solubility(2) and a regression-derived equation(3), suggests the potential for bioconcentration in aquatic organisms is low(SRC).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), albuterol, which has an estimated vapor pressure of 8.9X10-9 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase albuterol may be removed from the air by wet and dry deposition(SRC).

Adverse Effects · 1건

The primary adverse effects of albuterol therapy are tremors and nervousness, and although they can occur at any age, they are predominantly observed in children aged 2 to 6. Tremors result from the activation of β2-receptors found on motor nerve terminals, leading to an increase in intracellular cAMP. These adverse effects occur in approximately 1 in every 5 patients. Additional adverse effects include insomnia and nausea, which occur in approximately 1 in every 10 patients. Less common adverse effects may include fever, bronchospasm, vomiting, headache, dizziness, cough, allergic reactions, otitis media, epistaxis, increased appetite, urinary tract infections, dry mouth, gas, hyperhidrosis, pain, dyspepsia, hyperactivity, chills, lymphadenopathy, ocular pruritus, sweating, conjunctivitis, and dysphonia. Albuterol also has been shown to increase blood pressure levels and may cause hypokalemia. Although rare, occurrences of increased blood glucose concentrations, prolonged QTc interval, and ST-segment depression have been reported.

Exposure RoutesSystemic absorption is rapid following aerosol administration.
Toxicity Summary · 2건

Signs and Symptoms of Overdose

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

Effluent ConcentrationsAlbuterol has been reported in unspecified influent waters at a maximum concentration of 0.17 ug/L(1). Concentrations of <0.025 to 0.17 ug/L have been reported in unspecified sewage effluents(2).
Soil Adsorption/Mobility · 1건

The Koc of albuterol is estimated as 23(SRC), using a water solubility of 1.41X10+4 mg/L(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that albuterol is expected to have very high mobility in soil. However, the estimated pKa1 and pKa2 values for albuterol are 9.2 and 10.7, respectively(4), indicating that this compound may partially exist in the protonated form in the environment. Cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(5), suggesting that mobility may be much lower in some soils(SRC).

Human Toxicity Excerpts · 5건

/HUMAN EXPOSURE STUDIES/ During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. Some of the mothers were taking multiple medication during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital anomalies has not been established.

/HUMAN EXPOSURE STUDIES/ This study was designed to determine the threshold dose for toxicity, the potential for serious medical complications, and the medical care required after unintentional albuterol ingestion in children. This study was prospective and descriptive. Data were obtained on pediatric albuterol ingestions evaluated emergently as reported to three regional poison control centers. Data elements included dose ingested, physical findings, medical treatment, and outcome. During 18 months, 78 patients who ingested albuterol and who received urgent medical evaluation were identified. Mean age was 2.8 years. The amount ingested ranged from 0.2 to 8.8 mg/kg. The most commonly reported signs of toxicity were tachycardia (57%, 44/78), widened pulse pressure (50%, 27/54), hyperglycemia (50%, 12/24), agitation (45%, 35/78), low serum carbon dioxide (42%, 10/24), vomiting (26%, 20/78), and hypokalemia (26%, 9/35). We found a threshold dose of 1 mg/kg for three or more signs of toxicity (P < 0.01). No patient required any specific treatment for toxicity. Seventy-two percent of patients were discharged from medical care within six hours of ingestion. Albuterol overdose in children causes a variety of cardiovascular, neuromuscular, and metabolic effects that are usually benign. The threshold dose for the development of three or more signs of toxicity is 1 mg/kg or three to 10 times the recommended daily dose. Toxicity is short-lived and does not require specific therapy or hospital admission in most cases.

/SIGNS AND SYMPTOMS/ signs and symptoms of overdose including exaggeration of common adverse reactions, particularly angina, hypertension, hypokalemia, and seizures. Cardiac arrest may occur.

/SIGNS AND SYMPTOMS/ Albuterol also has been reported to cause maternal and fetal tachycardia and hyperglycemia (especially in patients with diabetes), as well as maternal hypotension, acute congestive heart failure, pulmonary edema, and death.

/CASE REPORTS/ Albuterol overdose can lead to tachycardia, hypotension, tremor, hypokalemia, and hyperglycemia in children. Hypoglycemia had been previously reported in only one child. A 3-year-old boy who ingested high-dose albuterol in this report /is described/. On arrival to the emergency department, the child was agitated and had noticeable restlessness, sinus tachycardia, mild hypokalemia (3.2 mEq/L), and hyperglycemia (187 mg/dL). Activated charcoal and intravenous hydration were given, and electrocardiogram monitoring was performed. Sinus tachycardia resolved within 4 to 6 hours. Hypoglycemia (45 mg/dL) was identified 4 hours after admission. The child recovered uneventfully within 24 hours with glucose replacement. This case suggests that hypoglycemia could be a late complication of acute albuterol overdose; thus, the period of observation should be extended in these cases.

Artificial Pollution SourcesAlbuterol's production and use as a bronchodilator(1) may result in its release to the environment through various waste streams(SRC).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Albuterol

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Environmental Bioconcentration · 1건

An estimated BCF of 3 was calculated for albuterol(SRC), using a water solubility of 1.41X10+4 mg/L(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

규제 정보

FDA Requirements · 3건

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl albuterol, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl albuterol sulfate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Albuterol Sulfate/

Certain other dosage form new animal drugs. Albuterol. Indications for use: for the immediate relief of bronchospasm and bronchoconstriction associated with reversible airway obstruction in horses. Limitations: Not for use in horses intended for food.

안전 데이터

wgk
3
rtecs
ZE4400000
ridadr
3249
HS 번호
2922509090
risk_code
22-39/23/24/25-23/24/25-11
hazard_code
Xn,T,F
safety_code
36-45-36/37-16-7
포장분류
III
위험 등급
6.1(b)
Hazard Classifications
Acute Tox. 4 OralAquatic Chronic 3Eye Irrit. 2Skin Sens. 1B
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
18559-94-9(Hazardous Substances Data)

Adrenergic bronchodilators act by stimulating beta2-adrenergic receptors in the lungs to relax bronchial smooth muscle, thereby relieving bronchospasm. /Adrenergic bronchodilators/

Primarily stimulates beta2-adrenergic receptors, with some minor beta1-adrenergic activity.

In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, date indicate that there is a population of beta2-receptors in the human heart existing in a concentration between 10% and 50% of cardiac beta-adrenergic receptors. The precise function of these receptors has not been established.

Activation of beta2-adrenergic receptors on airway smooth muscle leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP). This increase of cyclic AMP leads to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Albuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, this protecting against all bronchoconstrictor challenges. Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from most cells in the airway.

Biological Half-Life · 2건

The elimination half-life of inhaled or oral salbutamol has been recorded as being between 2.7 and 5 hours while the apparent terminal plasma half-life of albuterol has been documented as being approximately 4.6 hours.

Elimination: 3.8 to 6 hours.

Metabolism/Metabolites · 3건

Salbutamol is not metabolized in the lung but is converted in the liver to the 4'-o-sulphate (salbutamol 4'-O-sulfate) ester, which has negligible pharmacologic activity. It may also be metabolized by oxidative deamination and/or conjugation with glucuronide. Salbutamol is ultimately excreted in the urine as free drug and as the metabolite.

Metabolized through sulfate conjugation to its inactive 4'-O-sulfate ester by phenol sulphotransferase (PST). The (R)-enantiomer of albuterol is preferentially metabolized (ten fold) by PST compared to the (S)-enantiomer of albuterol.

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours

FDA Pharmacological Classification · 6건

QF8SVZ843E

ALBUTEROL

Mechanisms of Action [MoA] - Adrenergic beta2-Agonists

Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist

Albuterol is a beta2-Adrenergic Agonist. The mechanism of action of albuterol is as an Adrenergic beta2-Agonist.

ALBUTEROL

MeSH Pharmacological Classification · 3건

Agents that cause an increase in the expansion of a bronchus or bronchial tubes.

Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete.

Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.

Absorption, Distribution and Excretion · 6건

Following inhalation, salbutamol acts topically on bronchial smooth muscle and the drug is initially undetectable in the blood. After 2 to 3 hours low concentrations are seen, due presumably to the portion of the dose which is swallowed and absorbed in the gut. In particular, the systemic levels of salbutamol are low after inhalation of recommended doses. A trial conducted in 12 healthy male and female subjects using a higher dose (1,080 mcg of albuterol base) showed that mean peak plasma concentrations of approximately 3 ng/mL occurred after dosing when salbutamol was delivered using propellant HFA-134a. The mean time to peak concentrations (Tmax) was delayed after administration of VENTOLIN (salbutamol) HFA (Tmax = 0.42 hours) as compared with CFC-propelled salbutamol inhaler (Tmax = 0.17 hours).

After oral administration, 58-78% of the dose is excreted in the urine in 24 hours, approximately 60% as metabolites. A small fraction is excreted in the feces.

The volume of distribution recorded for intravenously administered salbutamol has been recorded as 156 +/- 38 L.

The renal clearance of salbutamol has been documented as 272 +/- 38 ml/min after oral administration and 291 +/- 70 ml/min after intravenous administration. Furthermore, the renal clearance of the predominant sulfate conjugate metabolite was recorded as 98.5 +/- 23.5 ml/min following oral administration.

Elimination: Renal, 69 to 90% (60% as the metabolite). Fecal, 4%.

Extended-release tablets: Availability is approximately 80% of that for tablets after a single dose, regardless of whether or not taken with food, but is 100% of that for immediate-release tablets at steady-state. Food decreases the rate of absorption without affecting bioavailability.

Tissue LocationsSmooth Muscle

용도 및 제조

Uses · 5건

Bronchodilator; tocolytic

Medication

Medication (Vet)

Use (kg; approx.) in Germany (2009): >250

For symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.

Formulations/Preparations · 3건

Oral Inhalation: Aerosol: 90 ug/metered spray Proventil Inhalation Aerosol (with chlorofluorohydrocarbon propellants and oleic acid), (Schering), Ventolin Inhalation Aerosol (with chlorofluorohydrocarbon propellants and oleic acid), (GlaxoSmithKline).

Oral: Solution 2 mg (of albuterol) per 5 mL Proventil Syrup (Schering). Tablets: 2 mg (of albuterol) Proventil (scored), (Schering); 4 mg (of albuterol) Proventil (scored), (Schering), Ventolin (scored), (GlaxoSmithKline). Tablets, extended release: 4 mg (of albuterol) Volmax (with povidone), (Muro), Vospire ER (Odyssey); 8 mg (of albuterol) Volmax (with povidone), (Muro), Vospire ER (Odyssey). Tablets, extended-release core, film-coated: 4 mg (core 2 mg with 2 mg immediate release) (of albuterol) Proventil Repetabs (with butylparaben), (Schering). /Albuterol Sulfate/

Oral Inhalation: Aerosol: 90 ug (of albuterol) per metered spray Proventil HFA (with alcohol, hydrofluoroalkane propellant, and oleic acid), (Schering), Ventolin HFA (with hydrofluoroalkane propellant), (GlaxoSmithKline); Solution, for nebulization: 0.21 mg (of albuterol) per mL (0.63 mg) AccuNeb (preservative-free; available as polyethylene vials), (Dey); 0.42 mg (of albuterol) per mL (1.25 mg) AccuNeb (preservative-free; available as polyethylene vials), (Dey); 0.083% (of albuterol) Albuterol Albuterol Sulfate Inhalation Solution (Dey), Proventil (preservative-free), (Schering). Solution, concentrate, for nebulization: 0.5% (of Albuterol) Albuterol Sulfate Inhalation Solution (with benzalkonium chloride), (Warrick), Proventil (with benzalkonium chloride), (Schering).

Use ClassificationPharmaceuticals
General Manufacturing InformationPreparation: LHC Lunts et al, ZA 6705591; US 3644353 (1968, 1972 both to Allen & Hanburys)
응용 분야 · 6건

개요Salbutamol 또는 albuterol은 천식 및 만성 폐색 성 폐 질환과 같은 상태에서 기관지 경련의 완화에 사용되는 단기 작용 β2-adrenergic receptor agonist입니다. 그것은 다른 상표 이름 중 Ventolin으로 판매됩니다. Salbutamol은 1968 년에 판매 될 첫 번째 선택적 β2 수용체 작용제였습니다.이 제품은 Allent & Hanburys가 Ventolin이라는 브랜드로 처음 판매되었습니다. 이 약물은 즉각적인 성공을 거두어 그 이후로 천식 치료에 사용되었습니다.

용도살부타몰(INN: salbutamol) 또는 알부테롤(USAN: albuterol)은 빠르게 반응하는 교감신경β2수용체작용제이며 천식과 만성 폐쇄성 폐질환과 같은 기관지 경련을 가라앉히는 데에 쓰인다.

개요Albuterol is a β2-adrenergic sympathomimetic amine with pharmacological similarities to terbutaline. It has almost no effect on β1-adrenoreceptors of the heart. It has expressed broncholytic effects—prevention or relief of bronchi spasms, lowering respiratory tract resistance, and increasing the vital capacity of the lungs.

역사In 1968, Salbutamol (Albuterol) will become the most prescribed bronchodilator in the world. Discovered by DAVID HARTLEY, DAVID JACK, LAWRENCE LUNTZ AND ALEXANDER RITCHIE of the British company Allen and Hanburys, former division of Glaxo-smith kline marketed under the name of Ventolin; who will stop the acute crisis and save the life of the asthmatic.In 2008, a study shows its action in cases of neuromuscular diseases.In February 2020, the U.S. Food and Drug Administration (FDA) approved the first generic of an albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm in people four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in people four years of age and older. The FDA granted approval of the generic albuterol sulfate inhalation aerosol to Perrigo Pharmaceutical.

용도immune suppressant, antineoplastic, antiviral

일반 설명Standard for Supelco MIP SPE cartridges. For more information request Supelco Literature T407075, T706019, T706030, T706020. Salbutamol is classified under the β-agonist group of chemicals which are known to possess powerful pharmacological activities.

상·하류 제품 정보

상류 원료

수소수소화 리튬알미늄
추가 설명 · 1건

정의ChEBI: A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).